Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni
583  

Gilead Subsidiary to Launch Authorized Generics of Epclusa and Harvoni

Gilead Sciences, Inc. announced plans to launch authorized generic versions of Epclusa® (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni® (ledipasvir 90mg/sofosbuvir 400mg), Gilead’s leading treatments for chronic hepatitis C virus (HCV), in the United States, through a newly created subsidiary, Asegua Therapeutics LLC. The authorized generics will ...

September 25, 2018
News  
The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir
810  

The Medicines Patent Pool and Gilead Sciences Sign Licence for Bictegravir

As part of a novel, once-daily, single-tablet HIV treatment, bictegravir could offer new option for people living with HIV in low- and middle-income countries Geneva, 4 October 2017 — The Medicines Patent Pool (MPP) today announced a licence with Gilead Sciences for bictegravir (BIC), now under ...

October 04, 2017
News  
IAS 2017: Closing ceremony exposes Gilead Sciences
723  

IAS 2017: Closing ceremony exposes Gilead Sciences

Conference funders, Gilead Sciences, named and shamed for its “insatiable greed” 9th International AIDS Conference on HIV Science in Paris (IAS 2017), drew to a close, in style. The community address delivered by Othoman Mellouk, during the final ceremony, exposed one of the key conference sponsors, ...

August 02, 2017
News